> Diabetes Research > Insulin Glargine & Insuline Glulisine

Insulin Glargine & Insuline Glulisine

Sanofi-Aventis announced recently the results of a study that demonstrated that patients using Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus patients treated with premix analog insulin.

Two abstracts from this study were highlighted at the American Diabetes Association’s 70th Annual Scientific Sessions (ADA). People following a basal-bolus insulin regimen use separate injections of a basal insulin and a mealtime insulin. This regimen is designed to address hyperglycemia before it happens by providing adequate insulin to cover fasting and prandial insulin needs.

A -premix insulin regimen combines prandial insulin analogs and the intermediate-acting insulin, NPH, in one injection. The results of this study demonstrated that patients using a basal bolus regimen (with Lantus and Apidra) reported improved outcomes and quality of life. “These results indicate that patients treated with a basal-bolus insulin regimen…demonstrate an improved quality of life and patient reported outcomes compared to those treated with premix analog insulin,” said Donald Simonson, MD, MPH, ScD, of the Endocrinology, Diabetes and Hypertension Division of Brigham and Women’s Hospital in Boston, Massachusetts, and principal investigator of the study.

Sanofi-Aventis strives to be diabetes patients’ partner in managing their condition by delivering innovative and integrated solutions for diabetes management. The company currently has insulin products, which include Lantus, Apidra, and Insuman (Lantus and Apidra are also available as injection pens; i.e., Lantus SoIoSTAR and Apidra SoIoSTAR). Following the formation of its Diabetes Division, Sanofi-Aventis has agreements with other companies for the development of blood glucose monitoring solutions and the potential first regenerative treatment for diabetes. Investigational compounds also in the pipeline include a once-daily injectable GLP-1 agonist as monotherapy and in combination with Lantus a long-acting insulin analog.

Related terms:

Related Posts:

» Tags: , , , , , ,

Related terms:

Leave a Reply

Your email address will not be published. Required fields are marked *